Key Details
Price
$0.00Annual Revenue
$77.00 KAnnual EPS
-$0.57Annual ROE
119.72%Beta
-1.73Events Calendar
Next earnings date:
N/ARecent quarterly earnings:
Nov 26, 2024Recent annual earnings:
June 30, 2020Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
Dec 05, 2019Analyst ratings
Recent major analysts updates
21 Aug '23 HC Wainwright & Co.
Buy17 July '23 EF Hutton
Buy30 Mar '23 EF Hutton
Buy28 Feb '23 EF Hutton
Buy27 Feb '23 HC Wainwright & Co.
Buy19 Aug '22 HC Wainwright & Co.
Buy29 Mar '22 HC Wainwright & Co.
Buy02 Dec '21 EF Hutton
BuyMarket Data
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Dividend
Nemaura Medical doesn't have historical dividend data
Profitability
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Efficiency
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Valuation
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Liquidity
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Cash Flow
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Institutional Ownership
Nemaura Medical to Present at the Maxim Group Emerging Growth in A.I. Conference
NMRD
GlobeNewsWire18 September 2023
Loughborough, England, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, announces today that CEO Dr. Faz Chowdhury will present business updates and developments at the Maxim Group Emerging Growth in A.I., virtual conference.
Nemaura Medical, Inc. (NMRD) Upgraded to Buy: What Does It Mean for the Stock?
NMRD
Zacks Investment Research23 August 2023
Nemaura Medical, Inc. (NMRD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
FAQ
- What is the primary business of Nemaura Medical?
- What is the ticker symbol for Nemaura Medical?
- Does Nemaura Medical pay dividends?
- What sector is Nemaura Medical in?
- What industry is Nemaura Medical in?
- What country is Nemaura Medical based in?
- When did Nemaura Medical go public?
- Is Nemaura Medical in the S&P 500?
- Is Nemaura Medical in the NASDAQ 100?
- Is Nemaura Medical in the Dow Jones?
- When was Nemaura Medical's last earnings report?
- When does Nemaura Medical report earnings?
- Should I buy Nemaura Medical stock now?
What is the primary business of Nemaura Medical?
Nemaura Medical is a healthcare company that develops innovative wearable devices for monitoring health. Their main product is a non-invasive glucose monitor, designed to help people manage diabetes. Nemaura aims to improve patient care and provide real-time health data for better lifestyle choices.
What is the ticker symbol for Nemaura Medical?
The ticker symbol for Nemaura Medical is NASDAQ:NMRD
Does Nemaura Medical pay dividends?
No, Nemaura Medical does not pay dividends
What sector is Nemaura Medical in?
Nemaura Medical is in the Healthcare sector
What industry is Nemaura Medical in?
Nemaura Medical is in the Medical Devices industry
What country is Nemaura Medical based in?
Nemaura Medical is headquartered in United States
When did Nemaura Medical go public?
Nemaura Medical's initial public offering (IPO) was on 05 February 2018
Is Nemaura Medical in the S&P 500?
No, Nemaura Medical is not included in the S&P 500 index
Is Nemaura Medical in the NASDAQ 100?
No, Nemaura Medical is not included in the NASDAQ 100 index
Is Nemaura Medical in the Dow Jones?
No, Nemaura Medical is not included in the Dow Jones index
When was Nemaura Medical's last earnings report?
Nemaura Medical's most recent earnings report was on 26 November 2024
When does Nemaura Medical report earnings?
The date for Nemaura Medical's next earnings report has not been announced yet
Should I buy Nemaura Medical stock now?
As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions